# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.
HC Wainwright & Co. analyst Edward White maintains Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
-SEC Filing
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Wedbush analyst Robert Driscoll reiterates Adicet Bio (NASDAQ:ACET) with a Outperform and maintains $5 price target.
Canaccord Genuity analyst John Newman reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $19 price target.
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.70) by...